*Note: For the investigational use of Adipose Tissue for clinical research and deployment.
CIDP also known as chronic inflammatory demyelinating polyneuropathy is an auto-immune disease of the nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. CIDP is closely related to Guillan-Barre Disease. Treatment for CIDP includes steroids and immunosuppressant drugs. Plasmapheresis (plasma exchange) and intravenous immunoglobulin (IVIG) therapy also commonly used.
Aggressive treatment is often necessary to prevent the loss of axons and subsequent effects on the function or mobility of the patient. Some cases progress and are resistant to medical therapy, making it difficult to manage symptoms. There is hope that treatment using cells from Adipose Tissue will mitigate some of the degenerative effects of CIDP neuropathy. Research is ongoing to evaluate the effects of this treatment on autoimmune conditions. This innovative therapy may provide new hope for patients with CIDP, mitigating the effects of chronic disease and the possibility of remission.